Pembrolizumab before surgery versus chemoradiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell cancer confirmed by tissue testing (biopsy).
- Your cancer is in the chest only and is planned for complete surgery (R0 resection), not spread to distant sites.
- Your lymph node checks near the collarbone do not show suspicious cancer spread.
- You feel well enough for treatment, with a performance status of 0 or 1, and you are age 18–75.
- You have not had any prior treatment for esophageal cancer (no surgery, chemotherapy, radiation, or immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before surgery can improve outcomes for people with locally advanced, operable esophageal squamous cell carcinoma. It may help shrink the tumor and improve the chance of successful surgery.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of an immunotherapy drug (serplulimab) and two chemotherapy drugs (nab-paclitaxel and cisplatin) given before surgery for esophageal cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improve outcomes for patients with stage IB to III esophageal squamous cell carcinoma.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.